Disc Medicine Appoints Nadim Ahmed to its Board of Directors

Core Insights - Disc Medicine, Inc. has appointed Nadim Ahmed to its Board of Directors, which is seen as a pivotal moment for the company as it advances its drug bitopertin towards commercialization in EPP [1][2] - Mr. Ahmed brings over 25 years of leadership experience in drug development and commercialization, having held significant roles at Cullinan Therapeutics, Bristol Myers Squibb, and Celgene [2] - The company is focused on developing novel treatments for serious hematologic diseases and aims to address various conditions through innovative therapeutic candidates [3] Company Developments - The appointment of Mr. Ahmed is expected to enhance Disc Medicine's capabilities in drug launches and development, particularly in hematological diseases [2] - The company anticipates multiple meaningful catalysts in the coming months, including a potential NDA filing and launch for bitopertin in EPP [2] - Disc Medicine is committed to building a portfolio of first-in-class therapeutic candidates targeting red blood cell biology, specifically heme biosynthesis and iron homeostasis [3]